Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium...
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Myeloma UK launches research programme to support myeloma clinical trials
- Broader inclusion criteria to double eligible cancer patients for clinical trials, finds study
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
Optimal JIT, CTCA to speed-up patient enrolment in cancer trials
Global contract research organisation PPD’s Accelerated Enrollment Solutions (AES) business unit Optimal just-in-time (JIT) has entered into a partnership with Cancer Treatment Centers of America (CTCA).
Janssen to trial mosaic-based HIV-1 preventive vaccine
Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners is set to initiate a Phase III clinical trial to evaluate an investigational preventive vaccine for HIV-1 infection.
GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
GlaxoSmithKline (GSK) has announced promising data for its Zejula (niraparib) drug as a maintenance therapy in the Phase III PRIMA clinical trial involving ovarian cancer patients.
Trials data suggests Cosentyx from Novartis will change psoriasis market
Cosentyx is set to change the landscape of the psoriasis market following results published by Novartis from a phase II study,
Amgen and Novartis suspend two Alzheimer’s prevention trials
Amgen and Novartis have announced the discontinuation of two pivotal Phase II/III clinical trials conducted in alliance with Banner Alzheimer's Institute to assess BACE1 inhibitor CNP520 for the prevention of the neurodegenerative disease.
Dolutegravir plus lamivudine yields positive data in HIV study
ViiV Healthcare has reported that the Phase III TANGO clinical trial of dolutegravir plus lamivudine met the primary endpoint of controlling HIV-1 infection in virally suppressed patients.
Pivotal to support two trials of new immunotherapy for MM and NSCLC
Contract research organisation (CRO) Pivotal is set to support two Phase II clinical trials of a new immunotherapy drug in metastatic melanoma (MM) and non-small cell lung cancer (NSCLC) patients.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.